AustralieFrV1, Main, Exploration, bibRecord, 006826

Pivotal Role of Innate and Adaptive Immunity in Anthracycline Chemotherapy of Established Tumors

Identifieur interne : 006826 ( Main/Exploration ); précédent : 006825; suivant : 006827

Pivotal Role of Innate and Adaptive Immunity in Anthracycline Chemotherapy of Established Tumors

Auteurs : Stephen R. Mattarollo [États-Unis, Australie] ; Sherene Loi [Belgique] ; Helene Duret [États-Unis] ; Yuting Ma [France] ; Laurence Zitvogel [France] ; Mark J. Smyth [États-Unis]

Source :

Cancer research : (Baltimore) [ 0008-5472 ] ; 2011.

RBID : Pascal:11-0352578

Descripteurs français

Pascal (Inist)
- Immunité naturelle, Immunité acquise, Anthracyclines, Chimiothérapie, Tumeur maligne.

English descriptors

KwdEn :
- Acquired immunity, Anthracyclins, Chemotherapy, Malignant tumor, Natural immunity.

Abstract

We show, in a series of established experimental breast adenocarcinomas and fibrosarcomas induced by carcinogen de novo in mice, that the therapeutic efficacy of doxorubicin treatment is dependent on CD8 T cells and IFN-γ production. Doxorubicin treatment enhances tumor antigen-specific proliferation of CD8 T cells in tumor-draining lymph nodes and promotes tumor infiltration of activated, IFN-γ-producing CD8 T cells. Optimal doxorubicin treatment outcome also requires both interleukin (IL)-1β and IL-17 cytokines, as blockade of IL-1β/IL-1R or IL-17A/IL-17Rα signaling abrogated the therapeutic effect. IL-23p19 had no observed role. The presence of γδ T cells, but not Jα18+ natural killer T cells, at the time of doxorubicin treatment was also important. In tumor samples taken from breast cancer patients prior to treatment with anthracycline chemotherapy, a correlation between CDBα, CD8β and IFN-γ gene expression levels and clinical response was observed, supporting their role in the therapeutic efficacy of anthracyclines in humans. Overall, these data strongly support the pivotal contribution of both innate and adaptive immunity in treatment outcomes of anthracycline chemotherapy.

Affiliations:

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: 001A70
to stream PascalFrancis, to step Curation: 004474
to stream PascalFrancis, to step Checkpoint: 001788
to stream Main, to step Merge: 006C39
to stream Main, to step Curation: 006826

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Pivotal Role of Innate and Adaptive Immunity in Anthracycline Chemotherapy of Established Tumors</title>
<author><name sortKey="Mattarollo, Stephen R" sort="Mattarollo, Stephen R" uniqKey="Mattarollo S" first="Stephen R." last="Mattarollo">Stephen R. Mattarollo</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Cancer Immunology Program, Peter MacCallum Cancer Centre</s1>
<s2>East Melbourne</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>East Melbourne</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>The University of Queensland Diamantina Institute, Princess Alexandra Hospital, Woolloongabba</s1>
<s2>Queensland</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>Queensland</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Loi, Sherene" sort="Loi, Sherene" uniqKey="Loi S" first="Sherene" last="Loi">Sherene Loi</name>
<affiliation wicri:level="3"><inist:fA14 i1="04"><s1>Breast Cancer Translational Research Laboratory JC Heuson, Jules Bordet Institute</s1>
<s2>Brussels</s2>
<s3>BEL</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
<placeName><settlement type="city">Bruxelles</settlement>
<region nuts="2">Région de Bruxelles-Capitale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Duret, Helene" sort="Duret, Helene" uniqKey="Duret H" first="Helene" last="Duret">Helene Duret</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Cancer Immunology Program, Peter MacCallum Cancer Centre</s1>
<s2>East Melbourne</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>East Melbourne</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ma, Yuting" sort="Ma, Yuting" uniqKey="Ma Y" first="Yuting" last="Ma">Yuting Ma</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>INSERM U1015, Institut Gustave Roussy</s1>
<s2>Villejuif</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>Villejuif</wicri:noRegion>
<wicri:noRegion>Institut Gustave Roussy</wicri:noRegion>
<wicri:noRegion>Villejuif</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Zitvogel, Laurence" sort="Zitvogel, Laurence" uniqKey="Zitvogel L" first="Laurence" last="Zitvogel">Laurence Zitvogel</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>INSERM U1015, Institut Gustave Roussy</s1>
<s2>Villejuif</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>Villejuif</wicri:noRegion>
<wicri:noRegion>Institut Gustave Roussy</wicri:noRegion>
<wicri:noRegion>Villejuif</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Center of Clinical Investigations in Biotherapies of Cancer CICBT 507, Institut Gustave Roussy</s1>
<s2>Villejuif</s2>
<s3>FRA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>Villejuif</wicri:noRegion>
<wicri:noRegion>Institut Gustave Roussy</wicri:noRegion>
<wicri:noRegion>Villejuif</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Faculté de Médecine de l'Université Paris-Sud XI</s1>
<s2>Le Kremlin-Bicêtre</s2>
<s3>FRA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>Le Kremlin-Bicêtre</wicri:noRegion>
<wicri:noRegion>Faculté de Médecine de l'Université Paris-Sud XI</wicri:noRegion>
<wicri:noRegion>Faculté de Médecine de l'Université Paris-Sud XI</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Smyth, Mark J" sort="Smyth, Mark J" uniqKey="Smyth M" first="Mark J." last="Smyth">Mark J. Smyth</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Cancer Immunology Program, Peter MacCallum Cancer Centre</s1>
<s2>East Melbourne</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>East Melbourne</wicri:noRegion>
</affiliation>
<affiliation wicri:level="4"><inist:fA14 i1="02"><s1>Department of Pathology, University of Melbourne</s1>
<s2>Melbourne, Victoria</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
<orgName type="university">Université de Melbourne</orgName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">11-0352578</idno>
<date when="2011">2011</date>
<idno type="stanalyst">PASCAL 11-0352578 INIST</idno>
<idno type="RBID">Pascal:11-0352578</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001A70</idno>
<idno type="wicri:Area/PascalFrancis/Curation">004474</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001788</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">001788</idno>
<idno type="wicri:doubleKey">0008-5472:2011:Mattarollo S:pivotal:role:of</idno>
<idno type="wicri:Area/Main/Merge">006C39</idno>
<idno type="wicri:Area/Main/Curation">006826</idno>
<idno type="wicri:Area/Main/Exploration">006826</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Pivotal Role of Innate and Adaptive Immunity in Anthracycline Chemotherapy of Established Tumors</title>
<author><name sortKey="Mattarollo, Stephen R" sort="Mattarollo, Stephen R" uniqKey="Mattarollo S" first="Stephen R." last="Mattarollo">Stephen R. Mattarollo</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Cancer Immunology Program, Peter MacCallum Cancer Centre</s1>
<s2>East Melbourne</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>East Melbourne</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>The University of Queensland Diamantina Institute, Princess Alexandra Hospital, Woolloongabba</s1>
<s2>Queensland</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>Queensland</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Loi, Sherene" sort="Loi, Sherene" uniqKey="Loi S" first="Sherene" last="Loi">Sherene Loi</name>
<affiliation wicri:level="3"><inist:fA14 i1="04"><s1>Breast Cancer Translational Research Laboratory JC Heuson, Jules Bordet Institute</s1>
<s2>Brussels</s2>
<s3>BEL</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
<placeName><settlement type="city">Bruxelles</settlement>
<region nuts="2">Région de Bruxelles-Capitale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Duret, Helene" sort="Duret, Helene" uniqKey="Duret H" first="Helene" last="Duret">Helene Duret</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Cancer Immunology Program, Peter MacCallum Cancer Centre</s1>
<s2>East Melbourne</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>East Melbourne</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ma, Yuting" sort="Ma, Yuting" uniqKey="Ma Y" first="Yuting" last="Ma">Yuting Ma</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>INSERM U1015, Institut Gustave Roussy</s1>
<s2>Villejuif</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>Villejuif</wicri:noRegion>
<wicri:noRegion>Institut Gustave Roussy</wicri:noRegion>
<wicri:noRegion>Villejuif</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Zitvogel, Laurence" sort="Zitvogel, Laurence" uniqKey="Zitvogel L" first="Laurence" last="Zitvogel">Laurence Zitvogel</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>INSERM U1015, Institut Gustave Roussy</s1>
<s2>Villejuif</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>Villejuif</wicri:noRegion>
<wicri:noRegion>Institut Gustave Roussy</wicri:noRegion>
<wicri:noRegion>Villejuif</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Center of Clinical Investigations in Biotherapies of Cancer CICBT 507, Institut Gustave Roussy</s1>
<s2>Villejuif</s2>
<s3>FRA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>Villejuif</wicri:noRegion>
<wicri:noRegion>Institut Gustave Roussy</wicri:noRegion>
<wicri:noRegion>Villejuif</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Faculté de Médecine de l'Université Paris-Sud XI</s1>
<s2>Le Kremlin-Bicêtre</s2>
<s3>FRA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>Le Kremlin-Bicêtre</wicri:noRegion>
<wicri:noRegion>Faculté de Médecine de l'Université Paris-Sud XI</wicri:noRegion>
<wicri:noRegion>Faculté de Médecine de l'Université Paris-Sud XI</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Smyth, Mark J" sort="Smyth, Mark J" uniqKey="Smyth M" first="Mark J." last="Smyth">Mark J. Smyth</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Cancer Immunology Program, Peter MacCallum Cancer Centre</s1>
<s2>East Melbourne</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>East Melbourne</wicri:noRegion>
</affiliation>
<affiliation wicri:level="4"><inist:fA14 i1="02"><s1>Department of Pathology, University of Melbourne</s1>
<s2>Melbourne, Victoria</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
<orgName type="university">Université de Melbourne</orgName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Cancer research : (Baltimore)</title>
<title level="j" type="abbreviated">Cancer res. : (Baltimore)</title>
<idno type="ISSN">0008-5472</idno>
<imprint><date when="2011">2011</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Cancer research : (Baltimore)</title>
<title level="j" type="abbreviated">Cancer res. : (Baltimore)</title>
<idno type="ISSN">0008-5472</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Acquired immunity</term>
<term>Anthracyclins</term>
<term>Chemotherapy</term>
<term>Malignant tumor</term>
<term>Natural immunity</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Immunité naturelle</term>
<term>Immunité acquise</term>
<term>Anthracyclines</term>
<term>Chimiothérapie</term>
<term>Tumeur maligne</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We show, in a series of established experimental breast adenocarcinomas and fibrosarcomas induced by carcinogen de novo in mice, that the therapeutic efficacy of doxorubicin treatment is dependent on CD8 T cells and IFN-γ production. Doxorubicin treatment enhances tumor antigen-specific proliferation of CD8 T cells in tumor-draining lymph nodes and promotes tumor infiltration of activated, IFN-γ-producing CD8 T cells. Optimal doxorubicin treatment outcome also requires both interleukin (IL)-1β and IL-17 cytokines, as blockade of IL-1β/IL-1R or IL-17A/IL-17Rα signaling abrogated the therapeutic effect. IL-23p19 had no observed role. The presence of γδ T cells, but not Jα18+ natural killer T cells, at the time of doxorubicin treatment was also important. In tumor samples taken from breast cancer patients prior to treatment with anthracycline chemotherapy, a correlation between CDBα, CD8β and IFN-γ gene expression levels and clinical response was observed, supporting their role in the therapeutic efficacy of anthracyclines in humans. Overall, these data strongly support the pivotal contribution of both innate and adaptive immunity in treatment outcomes of anthracycline chemotherapy.</div>
</front>
</TEI>
<affiliations><list><country><li>Australie</li>
<li>Belgique</li>
<li>France</li>
<li>États-Unis</li>
</country>
<region><li>Région de Bruxelles-Capitale</li>
<li>Victoria (État)</li>
</region>
<settlement><li>Bruxelles</li>
<li>Melbourne</li>
</settlement>
<orgName><li>Université de Melbourne</li>
</orgName>
</list>
<tree><country name="États-Unis"><noRegion><name sortKey="Mattarollo, Stephen R" sort="Mattarollo, Stephen R" uniqKey="Mattarollo S" first="Stephen R." last="Mattarollo">Stephen R. Mattarollo</name>
</noRegion>
<name sortKey="Duret, Helene" sort="Duret, Helene" uniqKey="Duret H" first="Helene" last="Duret">Helene Duret</name>
<name sortKey="Smyth, Mark J" sort="Smyth, Mark J" uniqKey="Smyth M" first="Mark J." last="Smyth">Mark J. Smyth</name>
<name sortKey="Smyth, Mark J" sort="Smyth, Mark J" uniqKey="Smyth M" first="Mark J." last="Smyth">Mark J. Smyth</name>
</country>
<country name="Australie"><noRegion><name sortKey="Mattarollo, Stephen R" sort="Mattarollo, Stephen R" uniqKey="Mattarollo S" first="Stephen R." last="Mattarollo">Stephen R. Mattarollo</name>
</noRegion>
</country>
<country name="Belgique"><region name="Région de Bruxelles-Capitale"><name sortKey="Loi, Sherene" sort="Loi, Sherene" uniqKey="Loi S" first="Sherene" last="Loi">Sherene Loi</name>
</region>
</country>
<country name="France"><noRegion><name sortKey="Ma, Yuting" sort="Ma, Yuting" uniqKey="Ma Y" first="Yuting" last="Ma">Yuting Ma</name>
</noRegion>
<name sortKey="Zitvogel, Laurence" sort="Zitvogel, Laurence" uniqKey="Zitvogel L" first="Laurence" last="Zitvogel">Laurence Zitvogel</name>
<name sortKey="Zitvogel, Laurence" sort="Zitvogel, Laurence" uniqKey="Zitvogel L" first="Laurence" last="Zitvogel">Laurence Zitvogel</name>
<name sortKey="Zitvogel, Laurence" sort="Zitvogel, Laurence" uniqKey="Zitvogel L" first="Laurence" last="Zitvogel">Laurence Zitvogel</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 006826 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 006826 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:11-0352578
   |texte=   Pivotal Role of Innate and Adaptive Immunity in Anthracycline Chemotherapy of Established Tumors
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Pivotal Role of Innate and Adaptive Immunity in Anthracycline Chemotherapy of Established Tumors

Pivotal Role of Innate and Adaptive Immunity in Anthracycline Chemotherapy of Established Tumors

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri